International Journal of Clinical Oncology and Cancer Research

Research Article | | Peer-Reviewed |

CDA Formulations as Persuasive Good Cancer Drugs to Save Cancer Patients

Received: 11 January 2024    Accepted: 22 January 2024    Published: 5 February 2024
Views:       Downloads:

Share This Article

Abstract

The objective of this study is to develop good cancer drugs to save cancer patients. Good cancer drugs are the drugs capable of inactivating abnormal methylation enzymes (MEs) to take out both cancer stem cells (CSCs) and cancer cells (CCs) by inducing these cells to undergo terminal differentiation, and to restore chemo-surveillance to save cancer patients. Bad cancer drugs are cytotoxic agents that can kill CCs but cannot affect CSCs, which can also destroy chemo-surveillance to contribute to the fatality of advanced cancer patients. Cell differentiation agent-2 (CDA-2) is a persuasive good cancer drug approved by the Chinese FDA. CDA-2 is a preparation of wound healing metabolites purified from urine, which can serve as a model for the development of CDA formulations as good cancer drugs. Wound healing metabolites active as differentiation inducers (DIs) and differentiation helper inducers (DHIs) are the active players of chemo-surveillance created by the nature as allosteric regulators of abnormal methylation enzymes (MEs). The elimination of abnormal MEs is very critical to the success of cancer therapy. Wound healing is a simple matter that comes naturally, because the nature creates chemo-surveillance to ensure perfection of wound healing. Cancer is the consequence of wound unhealing due to the collapse of chemo-surveillance. Cancer therapy can also be a simple matter, if the therapy follows wound healing process. PSCs and CSCs are cells with abnormal MEs, which are protected by drug resistance and anti-apoptosis mechanisms. PSCs are the cells involved in wound healing. Efficient induction of terminal differentiation of PSCs is very critical to the success of wound healing. Natural DIs and DHIs are the partners of PSCs and CSCs in wound healing, which can easily access to PSCs and CSCs. If wound is not healed, PSCs are forced to evolve into CSCs and then to progress to faster growing CCs. CCs display a high level of degradative enzymes to generate substrates for the syntheses of macro-molecules to support their faster growth. Natural DIs and DHIs may be rapidly degraded in CCs. A different set of unnatural DIs and DHIs may be necessary to achieve the induction of terminal differentiation of CCs. Thus, two sets of CDA formulations, one CDA-CSC with natural DIs and DHIs, and another CDA-CC with non-natural DIs and DHIs to accomplish induction of terminal differentiation of both CSCs and CCs to achieve effective therapy of cancer.

DOI 10.11648/ijcocr.20240901.13
Published in International Journal of Clinical Oncology and Cancer Research (Volume 9, Issue 1, April 2024)
Page(s) 15-24
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Cancer Drugs, CDA, CSCs, DIs, DHIs, Differentiation Therapy

References
[1] Google search on cancer statistics-NCI.
[2] Liau MC, Fruehauf JP. It has been half a century since President Nixon declared war on cancer: Destabilization of abnormal methylation enzymes has the blissing of the nature to win the war on cancer. Adv Complement Alt Med. 2020; 6(1): 538-539.
[3] Liau MC, Craig CL. Wound healing metabolites to heal cancer and unhealed wounds. Intl Res J Oncol. 2022; 6(3): 8-20.
[4] Liau MC, Baker LL. Destruction promotes the proliferation of progenitor stem cells and cancer stem cells. Therefore, non-destruction strategy is a better choice for cancer therapy. J Pharmacol Pharmaceu Pharmacovigi. 2020; 4: 029. DOI: 10.24966/PPP-5649/100029.
[5] Liau MC, Craig CL, Baker LL. Wound healing process as the most appropriate modality of cancer therapy. Eur J Applied Sci. 2023; 11(1): 463-471.
[6] Liau MC, Craig CL, Baker LL. Wound healing process as the best strategy to save cancer patients. London J Med & Health Res. 2023; 23(13): in press.
[7] Liau MC, Szopa M, Burzynski B, Burzynski SR. Chemo-surveillance: A novel concept of the natural defense mechanism against cancer. Drugs Exptl Clin Res. 1987; 13(Suppl. 1): 77-82.
[8] Liau MC. A perfect cancer drug must be able to take out both cancer cells and cancer stem cells, and to restore the functionality of chemo-surveillance. 3rd International Conference on Medicinal Chemistry and Drug Design. 2021; page 13.
[9] Liau MC, Craig CL, Baker LL. Development of good cancer drugs effective against cancer stem cells. Intl Res J Oncol. 2023; 6(2): 238-247.
[10] Liau MC, Szopa M, Burzynski B, Burzynski SR. Quantitative assay of plasma and urinary peptides as an aid for the evaluation of patients undergoing Antineoplaston therapy. Drugs Exptl Clin Res. 1987; 13(Supply. 1): 61-70.
[11] Liau MC, Fruehauf JP. Winning formulas to fulfill cancer moonshot. Intl J Res Oncol. 2022; 1(1): 1-5.
[12] Liau MC, Craig CL, Baker LL. CDA formulations to fulfill cancer moonshot and to win the war on cancer. 2023; Intl J Res Oncol. 2023; 2(2): 1-8.
[13] Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes to combat cancer: The nature’s choice to win the war on cancer. Lambert Academic Publishing. 2020; 978-620-2-66889-7.
[14] Dvorak HF. Tumors: Wounds that do not heal. N Engl J Med. 1986; 315(26): 1650-1659.
[15] MacCarthy-Morrough L, Martin P. The hallmarks of cancer are also the hallmarks of wound healing. Science Signaling. 2020; 13: 648.
[16] Liau MC, Craig CL, Baker LL. No scar as an indication of perfect wound healing, ugly scar as imperfect wound healing and cancer as failed wound healing. J Cancer Tumor Intl. 2022; 12(1): 29-34.
[17] Liau MC, Craig CL, Baker LL. Wound unhealing as a grave issue of cancer. Intl Res J Oncol. 2023; 6(1): 97-103.
[18] Liau MC, Craig CL. On the mechanism of wound healing and the impact of wound on cancer evolution and cancer therapy. Intl Res J Oncol. 2021; 5(3): 25-31.
[19] Liau MC, Baker LL. The functionality of chemo-surveillance dictates the success of wound healing as well as cancer therapy. Nov Res Sci. 2021; 7(2): 1-3.
[20] Liau MC, Craig CL. Chemo-surveillance as a natural mechanism to ensure perfection of wound healing to avoid cancer evolution and to cure cancer. In: New Horizons in Medicine and Medical Research. 2022; Vol 6, Chapter 3. Print ISBN: 978-93-5547-607-4.
[21] Liau MC, Craig CL, Baker LL. Restoration of chemo-surveillance as a top priority to save cancer patients. Intl Res J Oncol. 2023; 6(2): 227-237.
[22] Liau MC, Baker LL. The impact of COVID-19 pandemic on cancer patients. Intl Res J Oncol. 2022; 6(4): 13-17.
[23] Liau MC, Chang CF, Giovanella BC. Demostration of an altered S-adenosylmethionine synthetase in human malignant tumors xenografted into athymic nude mice. J Natl Cancer Inst. 1980; 64(5): 1071-1075.
[24] Liau MC, Craig CL, Liau LL. Abnormal methylation enzymes as the most critical issue of cancer. Intl Res J Oncol. 2023; 6(2): 168-176.
[25] Liau MC, Craig CL, Baker LL. Exceptional allosteric regulation of methylation enzymes. In: Saraydin SU (edi.): Novel Research Aspects in Medicine and Medical Research. 2023; Vol. 4: 38-56. DOI: 10.9734/bpi/nramms/V4/19881D.
[26] Liau MC, Chang CF, Saunder GF, Tsai YH. S-Adenosylhomocysteine hydrolases as the primary target enzymes in androgen regulation of methylation complexes. Arch Biochem Biophys. 1981; 208(1): 261-272.
[27] Racanelli AC, Turner FB, Xie LY, Taylor SM, Moran RG. A mouse gene that coordinate epigenetic controls and transcriptional interference to achieve tissue specific expression. Mol Cell Biol. 2008; 28(2): 836-848.
[28] Liau MC, Hunt ME, Hurlbert RB. Role of ribosomal RNA methylases in the regulation of ribosome production. Biochemistry. 1976: 15(14): 3158-3164.
[29] Bernstein KA, Bleichert F, Bean JM, Cross FR, Baserga SJ. Ribosome biogenesis is sensed at the start cell cycle check point. Mol Biol Cell. 2007; 18(3): 953-964.
[30] Justilien Y, Ali SA, Jamieson L, Yin N, Cox AD, Der CJ, et al. ETC2-dependent rRNA synthesis is required for KRAS-TRP53-driven ling adenocarcinoma. Cancer Cell. 2017; 31(2): 256-269.
[31] Liau MC, Zhuang P, Chiou GCY. Identification of the tumor factor of abnormal methylation enzymes as the catalytic subunit of telomerase. Clin Oncol Cancer Res. 2010; 7(2): 86-96.
[32] Prudova A, Bauman Z, Braun A, Vitvitsky V, Lu SC, Banerjee R. S-Adenosylmethionine stabilizes cystathionine beta-synthase and modulates redox capacity. Proc Natl Acad Sci USA. 2006; 103(17): 6489-6494.
[33] Chiva P, Wallner C, Kaizer E. S-Adenosylmethionine metabolism in HL-60 cells: Effect of cell cycle and differentiation. Biochim Biophys Acta. 1988; 971(1): 38-45.
[34] Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes: Nature’s way to eradicate cancer stem cells. Online J Complement Alt Med. 2019; 2(5): 1-6. DOI: 10.33552/OJCAM.2019.02.000546.
[35] Virchow R. Die Cellular Pathologie in Ihrer Begrundung auf Physiologische und Pathologische Gewebelehve. Hirschwald. 1858; 16: 440.
[36] Liau MC, Lin GW, Hurlbert RB. Partial purification and characterization of tumor and liver S-adenosylmethionine synthetases. Cancer Res. 1977; 37(2): 427-435.
[37] Liau MC, Lee SS, Burzynski SR. Hypomethylation of nucleic acids: A key to the induction of terminal differentiation. Intl J Exptl Clin Chemother. 1989; 2: 187-199.
[38] Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, et al. Loss of 5-hydroxy- methylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 2012; 103(4): 670-676.
[39] Ficz GM, Gibben JG. Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence? Genomics. 2014; 104(5): 352-357.
[40] Liau MC, Chang CF, Becker FF. Alteration of S-adenosylmethionine synthetases during chemical hepatocarcinogenesis and in resulting carcinomas. Cancer Res. 1979; 39: 2113-2119.
[41] Kamparath BN, Liau MC, Burzynski B, Burzynski SR. Protective effect of Antineoplaston A10 in hepatocarcinogenesis induced by aflatoxin B1. Intl J Tiss React. 1990; 12(Suppl.): 43-50.
[42] Ho ATV, Palla AR, Blake MR, Yual ND, Wang YX, Magnusson KEG, et al. Prostaglandins E2 is essential for efficacious skeletal muscle stem function, augmenting regeneration and strength. Proc Natl Acad Sci USA. 2017; 114(26): 6675-6684.
[43] Liau MC, Kim JH, Fruehauf JP. In pursuance of differentiation inducers to combat cancer via targeting of abnormal methylation enzymes. J Cancer Tumor Intl. 2020; 10(2): 39-47.
[44] Liau MC, Kim JH, Fruehauf JP. Arachidonic acid and its metabolites as the surveillance differentiation inducers to protect healthy people from becoming cancer patients. Clin Pharmacol Toxicol Res. 2021; 4(1): 7-10.
[45] Riciotti E, FitzGerald GA. Prostaglandins and inflammation. Anteroscler Thromb Vasc Biol. 2011; 31(5): 986-1000.
[46] Itkin T, Rafii S. Leukemia cells ”gas up” leaky bone marrow blood vessels. Cancer Cell. 2017; 32(3): 276-278.
[47] Passaro D, Di Tullio A, Abarrategi A, Rousault-Pierre K, Foster K, Ariza-McNaughton L, et al. Increased vascular permeability in the bone marrow microenvironment contribute to disease progression and drug response in acute myeloid leukemia. Cancer Cell. 2017; 32(3): 324-341.
[48] Williamson PJ, Kruger AR, Reynolds PJ, Hamlin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndromes. Br J Haemato. 1994; 87(4): 743-745.
[49] Boula A, Vougarelis M, Giannouli S, Katrinakis G, Psyllaki M, Pontikoglou C, et al. Effect of CA2 of antitumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res. 2006; 12(10): 3099-3108.
[50] Counter CM, Gupta J, Harley CB, Leber B. Telomerase activity in normal leukocytes and hematological malignancies. Blood. 1995; 85(9): 2315-2320.
[51] Fu C, Chen Z. Telomerase activities in myelodysplastic syndromes. Chin Med J (Engl). 2002; 115(10): 1475-1478.
[52] Woll PS, Kjallquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014; 25(6): 794-808.
[53] Liau MC. Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof. US Patent. 2007; 7232578.B2.
[54] Ma J. Differentiation therapy of malignant tumor and leukemia. CISCO Treaties on the Education of Clinical Oncology. 2007; 480-486.
[55] Santi DV, Norment A, Garret CE. Covalent bond formation between a DNA-cytosine methyltransferase of DNA containing 5-azacytosine. Proc Natl Acad Sci USA. 1984; 81(22): 6993-6997.
[56] Liau MC, Baker LL. Abnormal methylation enzymes as the bullseye of targeted cancer therapy. Nov Res Sci. 2021; 7(4): 1-3.
[57] Prassana P, Shack S, Wilson VL, Samid D. Phenylacetate in chemoprevention of 5-aza-2’-deoxycytidine induced carcinogenesis. Clin Cancer Res. 1995; 1(18): 865-871.
[58] Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, et al. Induction of tumor in mice by genomic hypomethylation. Science. 2003; 300(5618): 489-492.
[59] Palii SS, van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-aza-2’deoxycytidine induces reversible DNA damage that is distinctly influenced by DNA-methyltransferase 1 and 3B. Mol Cell Biol. 2008; 28(2): 752-771.
[60] Kizietepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, et al. 5-Azacytidine, a methyltransferase inhibitor, induces ATR-mediated DNA-double strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicine and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007; 6(6): 1718-1727.
[61] Yang Q, Wu F, Wang F, Cai K, Zhang Y, Sun Q, et al. Impact of DNA methyltransferase inhibitor 5-azacytidine on cardiac development of zebrafish in vivo and cardiomyocyte proliferation, apoptosis, and the homeostasis of gene expression in vitro. J Cell Biochem. 2019; 120(10): 17459-17471.
[62] Feng F, Li Q, Ling CQ, Zhang Y, Qin F, Wang F, et al. Phase III clinical trials of the cell differentiaition agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma. Chin J Clin Oncol. 2005; 2(4): 706-716.
[63] Liau MC, Fruehauf PA, Zheng ZH, Fruehauf JP. Development of synthetic cell differentiation agent formulations for the prevention and therapy of cancer via targeting of cancer stem cells. Cancer Stu Ther J. 2019; 4(1): 1-15.
[64] Huang M, Ye Y, Chen S, Chai JR, Wang ZY. Use of all trans-retinoic acid in the treatment of promyelocytic leukemia. Blood. 1988; 72: 567-572.
[65] Bourgead MF, Besancon F. Induction of 2’,5’-oligoadenylate synthetase by retinoic acid in two transformed human cell lines. Cancer Res. 1984; 44: 5355-5360.
[66] Morley JE. Hormone, aging and endocrines in the elderly. In Felig P, Frohman LA, “Endocrinology and Metabolism, 4th (edn), McGrow-Hill, Inc., Medical Publishing Division, New York. 2001; 1455-1482.
[67] Liau MC, Huang Li, Lee JH, Chen SC, Kuo SC. Development of differentiation helper inducers for the differentiation therapy of cancer. Chin Pharm J. 1998; 50(5): 289-303.
[68] Liau MC, Ashraf A, Lee SS, Hendry LB, Burzynski SR. Riboflavin as a minor anti-cancer component of A2 and A5. Intl J Tiss React. 1990; 12(Suppl.): 19-26.
[69] Liau MC, Liau CP. Methyltransferase inhibitors as excellent differentiation helper inducers for the differentiation therapy of cancer. Bull Chin Cancer. 2002; 11(3): 166-168.
[70] Liau MC, Kim JH, Fruehauf JP. Potentiation of ATRA activity in HL-60 cells by targeting methylation enzymes. J Pharmacol Pharmaceu Pharmacovigi. 2019. 3: 009. DOI: 10.24966/PPP-5649/100009.
Cite This Article
  • APA Style

    Liau, M. C., Craig, C. L., Baker, L. L. (2024). CDA Formulations as Persuasive Good Cancer Drugs to Save Cancer Patients. International Journal of Clinical Oncology and Cancer Research, 9(1), 15-24. https://doi.org/10.11648/ijcocr.20240901.13

    Copy | Download

    ACS Style

    Liau, M. C.; Craig, C. L.; Baker, L. L. CDA Formulations as Persuasive Good Cancer Drugs to Save Cancer Patients. Int. J. Clin. Oncol. Cancer Res. 2024, 9(1), 15-24. doi: 10.11648/ijcocr.20240901.13

    Copy | Download

    AMA Style

    Liau MC, Craig CL, Baker LL. CDA Formulations as Persuasive Good Cancer Drugs to Save Cancer Patients. Int J Clin Oncol Cancer Res. 2024;9(1):15-24. doi: 10.11648/ijcocr.20240901.13

    Copy | Download

  • @article{10.11648/ijcocr.20240901.13,
      author = {Ming Cheng Liau and Christine Liau Craig and Linda Liau Baker},
      title = {CDA Formulations as Persuasive Good Cancer Drugs to Save Cancer Patients},
      journal = {International Journal of Clinical Oncology and Cancer Research},
      volume = {9},
      number = {1},
      pages = {15-24},
      doi = {10.11648/ijcocr.20240901.13},
      url = {https://doi.org/10.11648/ijcocr.20240901.13},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.ijcocr.20240901.13},
      abstract = {The objective of this study is to develop good cancer drugs to save cancer patients. Good cancer drugs are the drugs capable of inactivating abnormal methylation enzymes (MEs) to take out both cancer stem cells (CSCs) and cancer cells (CCs) by inducing these cells to undergo terminal differentiation, and to restore chemo-surveillance to save cancer patients. Bad cancer drugs are cytotoxic agents that can kill CCs but cannot affect CSCs, which can also destroy chemo-surveillance to contribute to the fatality of advanced cancer patients. Cell differentiation agent-2 (CDA-2) is a persuasive good cancer drug approved by the Chinese FDA. CDA-2 is a preparation of wound healing metabolites purified from urine, which can serve as a model for the development of CDA formulations as good cancer drugs. Wound healing metabolites active as differentiation inducers (DIs) and differentiation helper inducers (DHIs) are the active players of chemo-surveillance created by the nature as allosteric regulators of abnormal methylation enzymes (MEs). The elimination of abnormal MEs is very critical to the success of cancer therapy. Wound healing is a simple matter that comes naturally, because the nature creates chemo-surveillance to ensure perfection of wound healing. Cancer is the consequence of wound unhealing due to the collapse of chemo-surveillance. Cancer therapy can also be a simple matter, if the therapy follows wound healing process. PSCs and CSCs are cells with abnormal MEs, which are protected by drug resistance and anti-apoptosis mechanisms. PSCs are the cells involved in wound healing. Efficient induction of terminal differentiation of PSCs is very critical to the success of wound healing. Natural DIs and DHIs are the partners of PSCs and CSCs in wound healing, which can easily access to PSCs and CSCs. If wound is not healed, PSCs are forced to evolve into CSCs and then to progress to faster growing CCs. CCs display a high level of degradative enzymes to generate substrates for the syntheses of macro-molecules to support their faster growth. Natural DIs and DHIs may be rapidly degraded in CCs. A different set of unnatural DIs and DHIs may be necessary to achieve the induction of terminal differentiation of CCs. Thus, two sets of CDA formulations, one CDA-CSC with natural DIs and DHIs, and another CDA-CC with non-natural DIs and DHIs to accomplish induction of terminal differentiation of both CSCs and CCs to achieve effective therapy of cancer.
    },
     year = {2024}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - CDA Formulations as Persuasive Good Cancer Drugs to Save Cancer Patients
    AU  - Ming Cheng Liau
    AU  - Christine Liau Craig
    AU  - Linda Liau Baker
    Y1  - 2024/02/05
    PY  - 2024
    N1  - https://doi.org/10.11648/ijcocr.20240901.13
    DO  - 10.11648/ijcocr.20240901.13
    T2  - International Journal of Clinical Oncology and Cancer Research
    JF  - International Journal of Clinical Oncology and Cancer Research
    JO  - International Journal of Clinical Oncology and Cancer Research
    SP  - 15
    EP  - 24
    PB  - Science Publishing Group
    SN  - 2578-9511
    UR  - https://doi.org/10.11648/ijcocr.20240901.13
    AB  - The objective of this study is to develop good cancer drugs to save cancer patients. Good cancer drugs are the drugs capable of inactivating abnormal methylation enzymes (MEs) to take out both cancer stem cells (CSCs) and cancer cells (CCs) by inducing these cells to undergo terminal differentiation, and to restore chemo-surveillance to save cancer patients. Bad cancer drugs are cytotoxic agents that can kill CCs but cannot affect CSCs, which can also destroy chemo-surveillance to contribute to the fatality of advanced cancer patients. Cell differentiation agent-2 (CDA-2) is a persuasive good cancer drug approved by the Chinese FDA. CDA-2 is a preparation of wound healing metabolites purified from urine, which can serve as a model for the development of CDA formulations as good cancer drugs. Wound healing metabolites active as differentiation inducers (DIs) and differentiation helper inducers (DHIs) are the active players of chemo-surveillance created by the nature as allosteric regulators of abnormal methylation enzymes (MEs). The elimination of abnormal MEs is very critical to the success of cancer therapy. Wound healing is a simple matter that comes naturally, because the nature creates chemo-surveillance to ensure perfection of wound healing. Cancer is the consequence of wound unhealing due to the collapse of chemo-surveillance. Cancer therapy can also be a simple matter, if the therapy follows wound healing process. PSCs and CSCs are cells with abnormal MEs, which are protected by drug resistance and anti-apoptosis mechanisms. PSCs are the cells involved in wound healing. Efficient induction of terminal differentiation of PSCs is very critical to the success of wound healing. Natural DIs and DHIs are the partners of PSCs and CSCs in wound healing, which can easily access to PSCs and CSCs. If wound is not healed, PSCs are forced to evolve into CSCs and then to progress to faster growing CCs. CCs display a high level of degradative enzymes to generate substrates for the syntheses of macro-molecules to support their faster growth. Natural DIs and DHIs may be rapidly degraded in CCs. A different set of unnatural DIs and DHIs may be necessary to achieve the induction of terminal differentiation of CCs. Thus, two sets of CDA formulations, one CDA-CSC with natural DIs and DHIs, and another CDA-CC with non-natural DIs and DHIs to accomplish induction of terminal differentiation of both CSCs and CCs to achieve effective therapy of cancer.
    
    VL  - 9
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • CDA Therapeutics, Inc., Missouri City, USA

  • CDA Therapeutics, Inc., Missouri City, USA

  • CDA Therapeutics, Inc., Missouri City, USA

  • Sections